Skip to main
CRBU

Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences (CRBU) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company that is well-positioned for success, with two promising CAR-T cell therapy candidates in its pipeline for the treatment of hematologic malignancies. The company has received multiple FDA designations, including RMAT, Fast Track, and Orphan Drug, which demonstrate the potential for expedited approval and commercialization. Initial data from its ongoing Phase 1 CaMMouflage trial shows strong efficacy results, including a 92% ORR and 91% MRD-negativity rate, indicating potential superiority over other BCMA or GPRC5D-targeted agents in the market. Analysts have reiterated a Buy rating and price target of $9 per share.

Bears say

Caribou Biosciences is reporting a narrower than expected net loss of $0.26 per share in 1Q26, with R&D and SG&A expenses coming in lower than projected. Despite still projecting a net loss for the full year, the company's cash position of $118.6M provides a runway into 2H27. With a lowered discount rate and a raised price target of $11 per share, the company reiterates a Buy rating.

Caribou Biosciences (CRBU) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Caribou Biosciences (CRBU) Forecast

Analysts have given Caribou Biosciences (CRBU) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Caribou Biosciences (CRBU) has a Strong Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Caribou Biosciences (CRBU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.